Silke Kapp-Schwoerer
Overview
Explore the profile of Silke Kapp-Schwoerer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
245
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cocciardi S, Saadati M, Weiss N, Spath D, Kapp-Schwoerer S, Schneider I, et al.
Hemasphere
. 2025 Jan;
9(1):e70060.
PMID: 39816531
This study aimed to evaluate the impact of the myelodysplasia-related gene (MRG) as well as additional gene mutations on outcomes in intensively treated patients with -mutated ( ) AML. Targeted...
2.
Heitmann J, Schlenk R, Dorfel D, Kayser S, Dohner K, Heuser M, et al.
J Hematol Oncol
. 2023 Aug;
16(1):96.
PMID: 37587502
Background: About half of AML patients achieving complete remission (CR) display measurable residual disease (MRD) and eventually relapse. FLYSYN is an Fc-optimized antibody for eradication of MRD directed to FLT3/CD135,...
3.
Dohner H, Weber D, Krzykalla J, Fiedler W, Kuhn M, Schroeder T, et al.
Lancet Haematol
. 2023 May;
10(7):e495-e509.
PMID: 37187198
Background: Acute myeloid leukaemia with mutated NPM1 is associated with high CD33 expression and intermediate-risk cytogenetics. The aim of this study was to evaluate intensive chemotherapy with or without the...
4.
Eberhardt N, Peters L, Kapp-Schwoerer S, Beer M, Beer A, Gruner B, et al.
Pathogens
. 2022 Mar;
11(3).
PMID: 35335672
Recent improvements in alveolar echinococcosis (AE) therapy can provide long-term disease control, and even allow structured treatment interruption in selected cases. Imaging has a pivotal role in monitoring disease activity,...
5.
Grunenberg A, Sala E, Kapp-Schwoerer S, Viardot A
Expert Opin Pharmacother
. 2022 Feb;
23(5):561-571.
PMID: 35193450
Introduction: T-cell acute lymphoblastic leukemia (T-ALL) is a rare but potentially life-threatening heterogeneous hematologic malignancy that requires prompt diagnosis and treatment by hematologists. So far, therapeutic advances have been achieved...
6.
Teich K, Krzykalla J, Kapp-Schwoerer S, Gaidzik V, Schlenk R, Paschka P, et al.
Haematologica
. 2021 May;
106(11):2986-2989.
PMID: 34047179
No abstract available.
7.
Kapp-Schwoerer S, Weber D, Corbacioglu A, Gaidzik V, Paschka P, Kronke J, et al.
Blood
. 2020 Dec;
136(26):3041-3050.
PMID: 33367545
Monitoring of measurable residual disease (MRD) provides prognostic information in patients with Nucleophosmin1-mutated (NPM1mut) acute myeloid leukemia (AML) and represents a powerful tool to evaluate treatment effects within clinical trials....
8.
Schlenk R, Paschka P, Krzykalla J, Weber D, Kapp-Schwoerer S, Gaidzik V, et al.
J Clin Oncol
. 2019 Dec;
38(6):623-632.
PMID: 31851556
Purpose: High CD33 expression in acute myeloid leukemia (AML) with mutated provides a rationale for the evaluation of gemtuzumab ozogamicin (GO) in this AML entity. We conducted a randomized trial...
9.
Rucker F, Agrawal M, Corbacioglu A, Weber D, Kapp-Schwoerer S, Gaidzik V, et al.
Blood
. 2019 Sep;
134(19):1608-1618.
PMID: 31554635
We performed serial measurable residual disease (MRD) monitoring in bone marrow (BM) and peripheral blood (PB) samples of 155 intensively treated patients with RUNX1-RUNX1T1+ AML, using a qRT-PC-based assay with...
10.
Pantic M, Pfeifer D, Kapp-Schwoerer S, Ihorst G, Becker H, Zeiser R, et al.
Leukemia
. 2019 Jul;
33(12):2956-2962.
PMID: 31350530
No abstract available.